Fentanyl Pectin Nasal Spray reduces breakthrough cancer pain intensity compared with placebo in people taking at least 60 mg daily oral morphine or equivalent.

摘要

Breakthrough pain is a significant problem for people with cancer.Patterns of breakthrough pain are often different from the pharmacokinetics of immediate release oral analgesics.Matching patterns of breakthrough pain with medications that work within the timeframe of breakthrough pain may improve breakthrough pain management.A comprehensive assessment includes evaluating breakthrough pain separately from persistent pain, using similar strategies for screening and assessing both types of pain.Fentanyl Pectin Nasal Spray (FPNS) provides an additional option to manage breakthrough cancer pain (BTCP).Patient education regarding the correct-use of medications for persistent and breakthrough pain and the appropriate use of novel routes of administration is important for optimal analgesic medication efficacy and safety.